Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03691714 · ClinicalTrials.gov registry record · Phase 2
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Trisha Wise-Draper.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT03691714 is a Phase 2 study that has completed, run by Trisha Wise-Draper. The registered enrollment target is 35 participants.
The verdict
NCT03691714, a Phase 2 study, has completed, sponsored by Trisha Wise-Draper.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer. Participants will receive both durvalumab and cetuximab.
Interventions
- DRUG Cetuximab
- DRUG Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03691714
The ClinicalTrials.gov registry entry for NCT03691714 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trisha Wise-Draper, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT03691714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03691714 about?
NCT03691714 is a clinical study titled "Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma". The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer. Participants will receive both durvalumab and cetuximab.
What is the current status of trial NCT03691714?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2018-10-23. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT03691714?
The interventions under investigation include: Cetuximab (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT03691714?
This trial is sponsored by Trisha Wise-Draper, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.